{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelioma%2C+Small+Cell+Lung+Cancer%2C+NSCLC&page=2", "query": { "condition": "Mesothelioma, Small Cell Lung Cancer, NSCLC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelioma%2C+Small+Cell+Lung+Cancer%2C+NSCLC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T14:48:20.928Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04672434", "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-11-19", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04672434" }, { "nct_id": "NCT05563272", "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Glioblastoma Multiforme", "Cholangiocarcinoma", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Soft Tissue Sarcoma", "Gastric Adenocarcinoma", "Malignant Mesothelioma (MM)", "Von Hippel Lindau", "Bladder Cancer", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 11, "start_date": "2023-06-06", "completion_date": "2025-05-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563272" }, { "nct_id": "NCT02071862", "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Triple-Negative Breast Cancer", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Mesothelioma", "Fumarate Hydratase (FH)-Deficient Tumors", "Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)", "Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors", "Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations", "Tumors Harboring Amplifications in the cMyc Gene" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Pac-CB", "type": "DRUG" }, { "name": "CBE", "type": "DRUG" }, { "name": "CB-Erl", "type": "DRUG" }, { "name": "CBD", "type": "DRUG" }, { "name": "CB-Cabo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-02", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2022-07-20", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 13, "location_summary": "San Francisco, California • Stanford, California • Sarasota, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071862" }, { "nct_id": "NCT01770665", "title": "Validation of the MiCK Assay", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mesothelioma, Small Cell Lung Cancer, NSCLC" ], "interventions": [], "intervention_types": [], "sponsor": "Pierian Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-06", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-09-16", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770665" }, { "nct_id": "NCT00066651", "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Malignant Mesothelioma", "Ovarian Cancer", "Pancreatic Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "SS1(dsFv)-PE38 immunotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066651" }, { "nct_id": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Carcinoma", "Adenoid Cystic Carcinoma", "Lung Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Mesothelioma", "Esophageal Cancer", "Any Solid Tumors Progressed After a Prior Immunotherapy", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma HNSCC", "Salivary Gland Carcinomas", "Head and Neck Cancers - Salivary Gland", "Head and Neck Cancers - Nasopharyngeal", "Head and Neck Cancers - Throat", "Small Cell Lung Cancer ( SCLC )", "Lung Cancer (Locally Advanced or Metastatic)", "Head and Neck Cancers - Tonsils", "Head and Neck Cancers Hypopharynx", "Head and Neck Cancers Larynx", "Head and Neck Cancers Lip", "Head and Neck Cancers Nasopharynx", "Head and Neck Cancers Oral Cavity", "Head and Neck Cancers", "Head and Neck Cancers Oropharynx", "Head and Neck Cancers Trachea" ], "interventions": [ { "name": "VMD-928 100 mg Tablet", "type": "DRUG" }, { "name": "VMD-928 Tablet and Pembrolizumab (200 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 242, "start_date": "2018-06-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 14, "location_summary": "Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556228" }, { "nct_id": "NCT00037817", "title": "Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Esophageal Cancers", "Primary Small Cell Lung Cancers", "Non-Small-Cell Lung Carcinoma", "Pleural Mesotheliomas", "Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Depsipeptide", "type": "BIOLOGICAL" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2002-05-17", "completion_date": "2009-11-09", "has_results": false, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00037817" }, { "nct_id": "NCT02062632", "title": "Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Carcinoma", "Hypopharyngeal Carcinoma", "Laryngeal Carcinoma", "Lymphoma", "Mesothelioma", "Metastatic Malignant Neoplasm in the Lung", "Metastatic Malignant Neoplasm in the Pleura", "Metastatic Malignant Neoplasm in the Spinal Cord", "Non-Small Cell Lung Carcinoma", "Sarcoma", "Small Cell Lung Carcinoma", "Thymic Carcinoma", "Thymoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Doxepin Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-04-14", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2019-10-01", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Green Bay", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02062632" }, { "nct_id": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Hepatocellular Cancer", "Mesothelioma", "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Nasopharyngeal Cancer", "Kidney Cancer", "Squamous Cell Cancer of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC), Non-squamous" ], "interventions": [ { "name": "TAK-500", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-04-14", "completion_date": "2025-01-06", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070247" }, { "nct_id": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Microsatellite Stable Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "Cervical Cancer", "Kidney Cancer", "Renal Cell Carcinoma", "Melanoma Stage IV", "Merkel Cell Carcinoma of Skin", "Mesothelioma", "Non-small Cell Lung Cancer", "Cutaneous Squamous Cell Carcinoma (CSCC)", "Urothelial Carcinoma Bladder", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "VET3-TGI", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "KaliVir Immunotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-09-16", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-06-25T14:48:20.928Z", "location_count": 7, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06444815" } ] }